secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001213900-24-096245
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CERo Therapeutics enters $20.6M stock purchase agreement and shareholders approve reverse split and equity plan
--------------------------------------------------------------------------------

- Entered into a purchase agreement with Keystone Capital Partners, LLC to sell up to $20,589,384.23 of common stock.
- Shareholders approved a reverse stock split at a ratio between 1:25 and 1:150, set by the board.
- Shareholders approved issuance of shares upon conversion of Series C Preferred and exercise of warrants from September 2024.
- Shareholders approved an increase of 20,845,391 shares under the 2024 Equity Incentive Plan.
- Company had previously sold 23,377,921 shares for $4.41 million under the prior purchase agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024096245/0001213900-24-096245-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024096245/ea0220614-8k_cerothera.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-096245

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer